MYC and neoplasm: Pre-clinically, the greatest sensitivity to ibrutinib was also seen in the co-amplified oesophageal models [15] and thus future research may focus on evaluating ibrutinib efficacy in dual c-MYC and HER2 highly co-amplified tumours (3/7, 43% of the evaluable population in this study).